Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity
G Olsson,
N Rehnqvist,
A Sjogren,
L Erhardt,
and
T Lundman
The effects of metoprolol treatment in patients surviving acute myocardial infarction have been investigated in a double-blind randomized study. The patients were stratified according to age, infarct size and type of ventricular arrhythmias before administration of metoprolol, 100 mg twice daily (n = 154), or placebo (n = 147). All patients were followed up for 36 months. There were 31 (29 cardiac) and 25 (20 cardiac) deaths in the placebo and metoprolol groups, respectively. Subgroup analyses showed a significant reduction of cardiac death in patients with a large infarct (32.1% with placebo versus 12.5% with metoprolol, p less than 0.05) as a result of active treatment. Sudden death rates were 14.7% in the placebo versus 5.8% in the metoprolol group (p less than 0.05). The incidence of nonfatal reinfarction was 21.1% in the placebo versus 11.7% in the metoprolol group (p less than 0.05). The reduction in nonfatal reinfarction was similar in all pretreatment risk strata. The difference between the two groups in cumulative number of cardiac deaths and patients experiencing nonfatal reinfarction increased throughout the study. Furthermore, cerebrovascular events (p less than 0.05) and coronary bypass surgery (p = 0.058) were more frequent in the placebo group. In conclusion, after 36 months of metoprolol treatment after myocardial infarction, there was a significant reduction of nonfatal reinfarction and sudden death in all patients and a reduction of cardiac death in those with a large infarct.
This article has been cited by other articles:

|
 |

|
 |
 
Y. Lu, Y. Zhang, H. Shan, Z. Pan, X. Li, B. Li, C. Xu, B. Zhang, F. Zhang, D. Dong, et al.
MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection
Cardiovasc Res,
December 1, 2009;
84(3):
434 - 441.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Onalan, B. E. Cumurcu, and L. Bekar
Complete Atrioventricular Block Associated With Concomitant Use of Metoprolol and Paroxetine
Mayo Clin. Proc.,
May 1, 2008;
83(5):
595 - 599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Sipahi, E. M. Tuzcu, K. E. Wolski, S. J. Nicholls, P. Schoenhagen, B. Hu, C. Balog, M. Shishehbor, W. A. Magyar, T. D. Crowe, et al.
{beta}-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials
Ann Intern Med,
July 3, 2007;
147(1):
10 - 18.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol.,
September 5, 2006;
48(5):
e247 - e346.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace,
September 1, 2006;
8(9):
746 - 837.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P Hjemdahl, S V Eriksson, C Held, L Forslund, P Nasman, and N Rehnqvist
Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS)
Heart,
February 1, 2006;
92(2):
177 - 182.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Amar, J. P. Cambou, E. Touze, V. Bongard, G. Jullien, A. Vahanian, G. Coppe, J. L. Mas, and on behalf of ECLAT1 Study Investigators
Comparison of Hypertension Management After Stroke and Myocardial Infarction: Results From ECLAT1--A French Nationwide Study
Stroke,
July 1, 2004;
35(7):
1579 - 1583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. T. Ko, P. R. Hebert, C. S. Coffey, A. Sedrakyan, J. P. Curtis, and H. M. Krumholz
{beta}-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction
JAMA,
July 17, 2002;
288(3):
351 - 357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Camm and Y. G. Yap
Clinical Trials of Antiarrhythmic Drugs in Postmyocardial Infarction and Congestive Heart Failure Patients
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2001;
6(1):
99 - 106.
[PDF]
|
 |
|

|
 |

|
 |
 
T. Houghton, N. Freemantle, and J. G.F. Cleland
Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials
Eur J Heart Fail,
September 1, 2000;
2(3):
333 - 340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L Forslund, P Hjemdahl, C Held, I Bjorkander, S.V Eriksson, U Brodin, and N Rehnqvist
Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from The Angina Prognosis Study In Stockholm (APSIS)
Eur. Heart J.,
June 1, 2000;
21(11):
901 - 910.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. C. Larsen, M. R. Stupey, C. G. Walance, K. K. Griffith, J. E. Cutler, J. Kron, and J. H. McAnulty
Recurrent Cardiac Events in Survivors of Ventricular Fibrillation or Tachycardia: Implications for Driving Restrictions
JAMA,
May 4, 1994;
271(17):
1335 - 1339.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Zarembski, P. E. Nolan Jr, M. K. Slack, and A. C. Caruso
Empiric Long-term Amiodarone Prophylaxis Following Myocardial Infarction: A Meta-Analysis
Arch Intern Med,
December 13, 1993;
153(23):
2661 - 2667.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Burris
{beta}-Blockers, Dyslipidemia, and Coronary Artery Disease: A Reassessment
Arch Intern Med,
September 27, 1993;
153(18):
2085 - 2092.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Olsson, J. Tuomilehto, and J. Wikstrand
MAPHY and the Two Arms of HAPPHY-Reply
JAMA,
December 15, 1989;
262(23):
3272 - 3273.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wikstrand, I. Warnold, G. Olsson, J. Tuomilehto, D. Elmfeldt, G. Berglund, the Advisory Committee, G. Olsson, J. Tuomilehto, I. Warnold, et al.
Primary Prevention With Metoprolol in Patients With Hypertension: Mortality Results From the MAPHY Study
JAMA,
April 1, 1988;
259(13):
1976 - 1982.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wikstrand, G. Westergren, G. Berglund, D. Bracchetti, A. Van Couter, C. A. Feldstein, K. S. Ming, K. Kuramoto, S. Landahl, E. Meaney, et al.
Antihypertensive Treatment With Metoprolol or Hydrochlorothiazide in Patients Aged 60 to 75 Years: Report From a Double-blind International Multicenter Study
JAMA,
March 14, 1986;
255(10):
1304 - 1310.
[Abstract]
[PDF]
|
 |
|
|